USA-based Tiziana Life Sciences has moved fast to strengthen its management team following this week’s announcement of the resignation of Kunwar Shailubhai as chief executive, chief scientific officer and board director, effective as of August 1. 19 July 2022
Swiss biopharma company Relief Therapeutics today announced that its collaboration partner, Acer Therapeutics for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs), has resubmitted its New Drug Application (NDA) for ACER-001 to the US Food and Drug Administration (FDA). 18 July 2022
Agios Pharmaceuticals, a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that effective August 8, 2022, Jackie Fouse will transition to the role of chairwomen of the board of directors and Brian Goff will assume the role of chief executive officer. 13 July 2022
A firm developing a novel vaccine technology, which could offer safer and more effective protection against infectious diseases, has appointed a new chief executive officer. 13 July 2022
Centauri Therapeutics, a UK-based immunotherapy company focused on the treatment of infectious diseases, has announced three senior appointments at once. 12 July 2022
Swiss clinical-stage biotech Vaccentis, which is developing patient-specific medicines, today announced the appointment of Martin Munte, a veteran leader in biotech and pharma. 12 July 2022
Privately-held German biotech Ariceum Therapeutics, which is focused on developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has named Serge Sagodira its chief business officer. 7 July 2022
US development-stage mRNA-technology company Kernal Biologics today announced the completion of a $25 million Series A led by Hummingbird Ventures. 7 July 2022
Swiss contract development and manufacturing organization Lonza has announced that its board of directors has appointed Maria Soler Nunez as its new head of group operations. 4 July 2022
Israeli generics giant Teva Pharmaceutical Industries announced today the appointment of Eric Hughes as executive vice president, global R&D and chief medical officer. 1 July 2022
Canadian clinical-stage biotech Zymeworks today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, as chief scientific officer, reporting directly to the chief executive Officer. 27 June 2022
US pharma giant Merck & Co has announced that Chirfi Guindo will lead Human Health Marketing as chief marketing officer for Merck Human Health, and will join Merck’s executive team, effective July 1, 2022. 23 June 2022
Just three months after Nutcracker Therapeutics’ announcement of receiving $167 million in Series C funding, three new leadership positions have been filled alongside the release of its oncology and disease-focused pipeline. 22 June 2022
Privately-held contract research organization BioAgilytix Labs has announced the appointment of Euan Menzies as chairman and chief executive. 21 June 2022
Swiss antibody-drug conjugate specialist ADC Therapeutics announced today it has appointed industry veteran David Gilman to the new role of chief business and strategy officer, reporting to chief executive Ameet Mallik effective July 1. 13 June 2022
Biotech funder and incubator Flagship Pioneering and Tessera Therapeutics, a biotechnology company pioneering GENE WRITING technology backed by Flagship, today announced that Michael Severino has joined Tessera as chief executive. 3 June 2022
US biotech major Gilead Sciences has announced that Stacey Ma will join the company as executive vice president, pharmaceutical development and manufacturing, and will become a member of the company’s senior leadership team, reporting to chairman and chief executive, Daniel O’Day. 3 June 2022
London-headquartered generics company Hikma Pharmaceuticals has announced that its chief executive Siggi Olafsson has resigned in order to ‘pursue other opportunities’. 26 May 2022
An Expert View from Robert Wessman, chairman and CEO at global pharmaceutical company Alvogen, and founder and chairman at biopharma specialist, Alvotech. 25 May 2022
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024